Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

September 20, 2018September 20, 2018

Adempas Seen to Benefit Idiopathic PAH Patients Who Fail to Respond to Revatio in Pilot Study

News, PAH News

Idiopathic pulmonary arterial hypertension (IPAH) patients who failed to respond to treatment with Revatio (sildenafil), either alone or combined with other phosphodiesterase type 5 inhibitors, may benefit by switching to Adempas (riociguat), according to ... Read more

August 27, 2018August 30, 2018

Higher Concentration of Inhaled Ventavis May Help PAH Patients Stick to Treatment, Study Suggests

News, PAH News

More pulmonary arterial hypertension (PAH) patients were able to achieve complete daily inhalations after switching to a more concentrated formulation of Ventavis (iloprost), which also reduced the duration of each treatment ... Read more

August 23, 2018August 29, 2018

Treatment with Milrinone Improves Heart Function in Patients with PH Due to Left Heart Disease, Study Finds

News, PH News

Intravenous treatment with the approved heart failure medicine milrinone leads to significant improvements in heart structure and function in patients with mild-to-moderate pulmonary hypertension (PH) due to left heart disease, ... Read more

July 11, 2018July 18, 2018

Incremental Shuttle Walk Distance Test May Help Detect Early PH, Study Reports

News

An easy and simple tool called the incremental shuttle walk distance test, or ISWD, appears promising to identify early signs of pulmonary hypertension (PH), according to a new study. ... Read more

June 4, 2018June 4, 2018

Phase 2 Trial of Potential Therapy for PH Related to Left Heart Disease Soon to Begin Enrolling Patients

News, PH News

A new Phase 2 study evaluating Tenax Therapeutic’s investigational levosimendan as a therapy for pulmonary hypertension (PH) associated with heart failure and preserved left ventricular ejection fraction (PH-HFpEF) — ... Read more

May 21, 2018May 21, 2018

#ATS2018 — Bellerophon Presenting Top-line Results Showing INOpulse’s Benefits in PH-COPD Patients

News, PH News

Bellerophon‘s positive top-line results from its Phase 2 trial testing INOpulse as a potential therapy for pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) will be presented at ... Read more

May 11, 2018May 11, 2018

Enzyme Involved in Energy Production May Become New Target for Early Stage PH Therapy

News, PH News

A project investigating the role of a special protein called PFKFB3 in pulmonary hypertension (PH) has been awarded a $2.2 million grant from the National Heart, Lung and Blood ... Read more

May 10, 2018May 10, 2018

INOpulse Therapy for PH Associated with COPD to Enter Phase 2b Trial in US

News, PH News

Bellerophon Therapeutics announced that is moving forward with a planned Phase 2b trial that will investigate INOpulse as a therapy for pulmonary hypertension associated with chronic obstructive pulmonary disease ... Read more

April 30, 2018April 30, 2018

Smooth Muscle and Other Cells Send Signals That Promote PH Progression, Early Study Finds

News, PH News

Signaling, or “crosstalk,” between smooth muscle and other cells in the lungs’ vasculature can promote the progression of pulmonary hypertension, research in mice shows. The findings point to mechanisms ... Read more

March 26, 2018March 26, 2018

Renal Function Decline Linked to Higher Risk of PH in Kidney Disease

News, PH News

Poor renal function is linked to an increased prevalence of pulmonary hypertension (PH) in patients with chronic kidney disease (CKD), a retrospective study suggests. The study, “Epidemiology and risk ... Read more

Pin It on Pinterest